Passage Bio Stock (NASDAQ:PASG)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$0.61

52W Range

$0.54 - $1.79

50D Avg

$0.66

200D Avg

$1.02

Market Cap

$38.88M

Avg Vol (3M)

$298.90K

Beta

1.19

Div Yield

-

PASG Company Profile


Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

58

IPO Date

Feb 28, 2020

Website

PASG Performance


PASG Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-108.39M$-138.39M$-185.73M
Net Income$-102.06M$-136.86M$-191.50M
EBITDA$-108.39M$-132.39M$-169.73M
Basic EPS-$-2.51$-3.59
Diluted EPS-$-2.51$-3.59

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 22Mar 06, 23 | 1:07 PM
Q3 22Nov 10, 22 | 10:26 AM
Q2 22Aug 06, 22 | 10:50 AM

Peer Comparison


TickerCompany
RVMDRevolution Medicines, Inc. Warrant
STOKStoke Therapeutics, Inc.
BDTXBlack Diamond Therapeutics, Inc.
CABACabaletta Bio, Inc.
FIXXQ32 Bio Inc.